目的 观察吉西他滨联合顺铂的化疗方案对晚期肺鳞癌及肺腺癌的临床疗效及生存差异.方法 肺鳞癌组47例及肺腺癌37例患者给予吉西他滨(1000 mg/m2)联合顺铂(75 mg/m2)化疗,每21天为一周期,共化疗4个周期.结果 肺鳞癌组PR为14例(29.8%),SD为21例(44.7%),PD为12例(25.5%),RR为29.8%,中位生存期为13个月,1年生存率为53.2%;肺腺癌组PR为10例(27.0%),SD为18例(48.6%),PD为9例(24.3%),RR为27.0%,中位生存期为9个月,1年生存率为27.0%;结论 吉西他滨联合顺铂对晚期肺癌及鳞癌的临床疗效相当,但肺鳞癌较肺腺癌具有较好的1年生存率及生存时间.%Objective To explore the effect of gemcitabine combined with cisplatin in treatment of advanced lung squamous carcinoma and lung adenocarcinoma and survival difference. Methods 47 patients with lung squamous carcinoma and 37 patients with lung adenocarcinoma were treated with gemcitabine ( 1000 mg/m2 ) and cisplatin (75 mg/m2 ). 21 days was a cycle, and the total treatment course was 4 cycles. Results In lung squamous carcinoma patients, PR was 14 cases ( 29. 8% ), SD was 21 cases ( 44.7% ), PD was 12 cases ( 25. 5% ), and RR was 29. 8%. The median survival time was 13 months and the 1-year survival rate was 53. 2% . In lung adenocarcinoma patients, PR was 10 cases ( 27. 0% ), SD was 18 cases ( 48. 6% ), PD was 9 cases ( 24. 3% ), and RR was 27. 0%. The median survival time was 9 months and the 1-year survival rate was 27. 0%. Conclusion Gemcitabine combined with cisplatin in treatment of advanced lung squamous carcinoma and lung adenocarcinoma has the similar clinical effect, but the 1 - year survival rate and survival time of patients with lung squamous carcinoma are better than those of patients with lung adenocarcinoma.
展开▼
